E
Erin Murphy
Researcher at Merck & Co.
Publications - 49
Citations - 17499
Erin Murphy is an academic researcher from Merck & Co.. The author has contributed to research in topics: Pembrolizumab & Immunotherapy. The author has an hindex of 30, co-authored 49 publications receiving 15077 citations. Previous affiliations of Erin Murphy include Schering-Plough.
Papers
More filters
Journal ArticleDOI
Involvement of chemokine receptors in breast cancer metastasis.
Anja Müller,Bernhard Homey,Hortensia Soto,Nianfeng Ge,Daniel Catron,Matthew E. Buchanan,Terri McClanahan,Erin Murphy,Wei Yuan,Stephan N. Wagner,Jose Luis Barrera,Alejandro Mohar,Emma Verastegui,Albert Zlotnik +13 more
TL;DR: It is reported that the chemokine receptors CXCR4 and CCR7 are highly expressed in human breast cancer cells, malignant breast tumours and metastases and their respective ligands CXCL12/SDF-1α and CCL21/6Ckine exhibit peak levels of expression in organs representing the first destinations of breast cancer metastasis.
Journal ArticleDOI
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines
Jochen Schmitz,Alexander Owyang,Elizabeth R. Oldham,Yaoli Song,Erin Murphy,Terril K. McClanahan,Gerard Zurawski,Mehrdad M. Moshrefi,Jinzhong Qin,Xiaoxia Li,Daniel M. Gorman,J. Fernando Bazan,Robert A. Kastelein +12 more
TL;DR: A member of theIL-1 family, IL-33, which mediates its biological effects via IL-1 receptor ST 2, activates NF-kappaB and MAP kinases, and drives production of T(H)2-associated cytokines from in vitro polarized T( H)2 cells is reported.
Journal ArticleDOI
IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers,Jared Lunceford,Michael Nebozhyn,Erin Murphy,Andrey Loboda,David Ross Kaufman,Andrew Albright,Jonathan D. Cheng,S. Peter Kang,Veena Shankaran,Sarina Anne Piha-Paul,Jennifer H. Yearley,Tanguy Y. Seiwert,Antoni Ribas,Terrill K. McClanahan +14 more
TL;DR: The T cell–inflamed GEP contained IFN-&ggr;–responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance, and these features were necessary, but not always sufficient, for clinical benefit.
Journal ArticleDOI
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
Razvan Cristescu,Robin Mogg,Mark Ayers,Andrew Albright,Erin Murphy,Jennifer H. Yearley,Xinwei Sher,Xiaoqiao Liu,Hongchao Lu,Michael Nebozhyn,Chunsheng Zhang,Jared Lunceford,Andrew K. Joe,Jonathan D. Cheng,Andrea L. Webber,Nageatte Ibrahim,Elizabeth R. Plimack,Patrick A. Ott,Tanguy Y. Seiwert,Antoni Ribas,Terrill K. McClanahan,Joanne E. Tomassini,Andrey Loboda,David Ross Kaufman +23 more
TL;DR: The potential for TMB and a T cell–inflamed GEP to jointly predict clinical response to pembrolizumab was assessed in >300 patient samples with advanced solid tumors and melanoma across 22 tumor types from four KEYNOTE clinical trials.
Journal ArticleDOI
IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis.
Jason R. Chan,Wendy M. Blumenschein,Erin Murphy,Caroline Diveu,Maria T. Wiekowski,Susan J. Abbondanzo,Linda Lucian,Richard Geissler,Scott E. Brodie,Alexa B. Kimball,Daniel M. Gorman,Kathleen M. Smith,Rene de Waal Malefyt,Robert A. Kastelein,Terrill K. McClanahan,Edward P. Bowman +15 more
TL;DR: Indirect intradermal administration of IL-23 in mouse skin initiates a tumor necrosis factor–dependent, but IL-17A–independent, cascade of events resulting in erythema, mixed dermal infiltrate, and epidermal hyperplasia associated with parakeratosis.